Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Publications

Durability of ChAdOx1 nCov-19 vaccination in people living with HIV.

Ogbe A. et al, (2022), JCI Insight

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

Clemens SAC. et al, (2021), Nature Communications, 12

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.

Clemens SAC. et al, (2021), Nat Commun, 12

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).

Flaxman A. et al, (2021), Lancet, 398, 981 - 990

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.

Frater J. et al, (2021), Lancet HIV, 8, e474 - e485

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.

Barrett JR. et al, (2021), Nat Med, 27

Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.

Ewer KJ. et al, (2021), Nat Med, 27

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.

Emary KRW. et al, (2021), Lancet, 397, 1351 - 1362

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Voysey M. et al, (2021), Lancet, 397, 881 - 891

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.

Barrett JR. et al, (2021), Nat Med, 27, 279 - 288

Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study.

Bach SP. et al, (2021), Lancet Gastroenterol Hepatol, 6, 92 - 105

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Voysey M. et al, (2021), Lancet, 397, 99 - 111

Status of primary and secondary mental healthcare of people with severe mental illness: An epidemiological study from the UK PARTNERS2 programme

Reilly S. et al, (2021), BJPsych Open, 7

Faecal immunochemical tests versus colonoscopy for post-poly pectomy surveillance: An accuracy, acceptability and economic study

Atkin W. et al, (2019), Health Technology Assessment, 23, I - 84

Include forthcoming?